NIGHTSTARX LIMITED Revenue and Competitors

London, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NIGHTSTARX LIMITED's estimated annual revenue is currently $16.1M per year.(i)

Employee Data

    NIGHTSTARX LIMITED's People

    NameTitleEmail/Phone
    Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
    #1
    $22.9M1144%£18MN/A
    #2
    $8.4M420%N/AN/A
    #3
    $69.7M34712%N/AN/A
    #4
    $234.1M7285%$5.7MN/A
    #5
    $165.2M8222%N/AN/A
    #6
    $19.3M967%N/AN/A
    #7
    $28.7M14317%N/AN/A
    #8
    $69.7M34721%N/AN/A
    #9
    $24.1M12025%N/AN/A
    #10
    $62.1M309N/AN/AN/A
    Add Company

    What Is NIGHTSTARX LIMITED?

    Nightstar Therapeutics plc (NASDAQ: NITE) is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

    keywords:N/A

    N/A

    Total Funding

    N/A

    Number of Employees

    $16.1M

    Revenue (est)

    N/A

    Employee Growth %

    N/A

    Valuation

    N/A

    Accelerator

    NIGHTSTARX LIMITED News

    2022-03-22 - Disease-specific assessment of Vision Impairment in Low ...

    Besides the VILL, only a limited number of PRO instruments were designed to ... LinBioscience, NightStarX, Novartis, Optos, Pixium Vision,...

    2022-03-22 - Purespring Positive About Prospects Despite Burst Biotech ...

    ... Therapeutics Limited and its AAV2-based one-time investigational ... manufacturing and controls (CMC) for its NightstaRx Therapeutics...

    2019-03-20 - Nightstar Therapeutics plc files 10-K

    Under the SME Scheme, our principal research subsidiary company, NightstaRx Limited, may be eligible to surrender the trading losses that